Navigation Links
A New Era Of Hope For Neglected Diseases

After a barren period when very few therapies were introduced for neglected diseases, which kill around 3m people a year and cause the loss of the equivalent of 92m years' of healthy life, there are now over 60 drug research projects underway.

In the PLoS Medicine analysis, which is based upon a 100-page report financed by the Wellcome Trust, Mary Moran of the London School of Economics found that around three-quarters of these projects are conducted under the umbrella of drug development Public-Private Partnerships (PPPs). Thirteen of them have already reached clinical trial stage and two are awaiting regulatory approval (rectal artesunate for malaria, and paromomycin for visceral leishmaniasis). These PPP-driven projects should result in six or seven new drug registrations in the next five years.

Research by Dr Moran and her colleagues has shown that PPPs have been a critical driver of this considerable increase in activity, and that the PPP approach brings together the best skills of both public and private partners. This model consequently performs better than either sector working alone when it comes to delivering safe, effective, affordable drugs for neglected diseases.

In a linked editorial, entitled "A New Era of Hope for the World's Most Neglected Diseases", the PLoS Medicine editors argue that Moran's findings are one of several indicators that the world is finally taking action against these diseases.

For example, the Gleneagles Communiqué arising out of this year's G8 summit specifically called for increased investment to encourage the development of tools for neglected-disease control.

Citation: Moran M (2005) A breakthrough in R&D for neglected diseases: New ways to get the drugs we need. PLoS Med 2(9): e302.
http:/?​dx.doi.org/?0.1371/​journal.pmed.0020302


'"/>

Source:PLoS


Page: 1

Related biology news :

1. A New Era of Hope for the Worlds Most Neglected Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New Era Hope For Neglected Diseases

(Date:9/4/2008)...een Syracuse University and the Serum Institute of...vaccines for children living in some of the most i...ently awarded $250,000 to a team of SU researchers...stry in the College of Arts and Sciences, to devel..., a severe form of diarrhea that affects infants a...
(Date:9/4/2008)...d a gene enhancer, known as HACNS1, that may have ...able human thumb, and possibly also modifications ...two legs, according to a paper published in Scien...to provide evidence of the existence of human-spec... in the human genome. , Dr. Shyam Prabhakar, f...
(Date:9/4/2008)...evelopment of powerful supercomputers capable of a...rk a technological milestone capable of bringing c...ring, and business worldwide. Researchers at the U...nd Atmospheric Science, collaborating with NCAR (N...nter for Ocean-Land-Atmospheric Studies) and the U...
(Date:9/4/2008)...ailable in German . , Cystic kidney disease, re...es of the excretory organs are characterized by ov...cteristic proteins in the renal cells. An internat...ists from DKFZ and Heidelberg University Hospitals...tigate these conditions. , The researchers intr...
Breaking Biology News(10 mins):Syracuse University partners with Serum Institute of India to develop vaccines for children 2Syracuse University partners with Serum Institute of India to develop vaccines for children 3Syracuse University partners with Serum Institute of India to develop vaccines for children 4Gene enhancer in evolution of human opposable thumb 2Gene enhancer in evolution of human opposable thumb 3Petascale climate modeling heats up at University of Miami 2Petascale climate modeling heats up at University of Miami 3Gaining a better understanding of kidney diseases 2ThalesNano Inc and sanofi aventis R 26D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time 5582 1ThalesNano Inc and sanofi aventis R 26D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time 5582 2Nyer Medical Group Inc Reports Revenues of 2418 9 Million With Net Loss of 24 16 Per Share for 3rd Quarter of Fiscal Year 2008 20049 1Nyer Medical Group Inc Reports Revenues of 2418 9 Million With Net Loss of 24 16 Per Share for 3rd Quarter of Fiscal Year 2008 20049 2Nyer Medical Group Inc Reports Revenues of 2418 9 Million With Net Loss of 24 16 Per Share for 3rd Quarter of Fiscal Year 2008 20049 3Drive Through Mastectomies Threaten Patients Lives 20044 1Drive Through Mastectomies Threaten Patients Lives 20044 2BioMarin to Host Research and Development Day June 5th 5577 1BioMarin to Host Research and Development Day June 5th 5577 2
...ants grow better if grown in a greenhouse in the c...chel van Ooteghem has designed a control system fo...n the new greenhouse, good climate control with su... crop yield but also a lower gas bill. , Factors ...ation and relative humidity must be controlled as ...
...ng to a review of the latest clinical trials, coro...heart, without the aid of a heart-lung machine, is...ffects for bypass patients. This review is feature...t was more common for doctors to perform artery by...d passing the blood through a heart-lung machine,?...
... in mice have indicated that the effects of prion ...The researchers said that their findings support d...ls of prion protein in the brains of people with p...suggest testing the efficacy of treatments in a ne...on-infected mice. , The researchers, Giovanna Mall...
...opsy data provide the strongest evidence yet that ...ery" disease but has a concrete biological basis. ...ildren,s Hospital Boston document abnormalities in... breathing, blood pressure, body heat, and arousal...ading cause of death in American infants after the...
Other Biology News:Prion disease treatable if caught early 2A potential biological cause for sudden infant death syndrome 2A potential biological cause for sudden infant death syndrome 3
(Date:9/4/2008)... - Revenues of $88.4 million, up 14% from the, pr...0.28, an increase of, 47% over last year,s third ...r-to-date operating cash flow of $62 million) - Ra...and earnings guidance, COLUMBIA, Md., Sept. 4 /PR...ion (Nasdaq: MATK ) today announced its financial...
(Date:9/4/2008)... The University of North Carolina-Chapel Hill ... Sciences, RESEARCH TRIANGLE PARK, N.C., Sept. 4 ...ciences and the University of North Carolina at,Ch...Center for Drug Safety,Sciences that will be led b...erts in drug-induced liver injury. As founding dir...
(Date:9/4/2008).../Xinhua-- Genesis,Pharmaceu...) ("Genesis" or,the "Company"), a leading pharmace...today announced that it completed a 40-for-1 rever...n trading under the symbol "GNPH.", Upon today,s ...trade,under the symbol "GTEC" and will begin tradi...
(Date:9/4/2008)...ymbol: MS, EDMONTON, Sept. 4 /PRNewswire-FirstCal...loper in the treatment of multiple sclerosis (MS),...tion (FDA) of the United States,has granted fast t...cotide,(MBP8298), for the treatment of secondary p...ently being evaluated in a U.S. pivotal phase III ...
Breaking Biology Technology:Martek Announces Third Quarter 2008 Financial Results 2Martek Announces Third Quarter 2008 Financial Results 3Martek Announces Third Quarter 2008 Financial Results 4Martek Announces Third Quarter 2008 Financial Results 5Martek Announces Third Quarter 2008 Financial Results 6Martek Announces Third Quarter 2008 Financial Results 7Martek Announces Third Quarter 2008 Financial Results 8Martek Announces Third Quarter 2008 Financial Results 9Martek Announces Third Quarter 2008 Financial Results 10New Hamner-UNC Center for Drug Safety Sciences 2New Hamner-UNC Center for Drug Safety Sciences 3Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol 2Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol 3BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA 2BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA 3BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA 4
... , An air impaction microbial assessmen...ted inhabitants,in your compressed air system,... INTRODUCTION, , Manufactur...sterile may use compressed,air in various applic...eration of conveyor belts,and/or aseptic cleani...
... , Many of these terms have more gener...cific to their application in cell culture and fer... a particular antibody or antigen from a sample (f...ing antigen or antibody to that,sample., ...in solution or suspension, to cells or ot...
...yle, L. Johnstone and L. Cottis, , ..., ,http://www.agen.com.au , , ...n was investigated as a means for producing,larg...ative to in vivo production. This,system best re...perate, flexible in its use,small enough to ena...
... , Introduction , This...,simple protocols for culturing cells in a BioFl...e modular,BioFlo 110 is offered with an extensiv...es to enable growth of,a wide variety of culture... bacterial cells. Complete kits are also,availab...
Other Biology Technology:Testing Compressed Air Lines for Microbiological Contamination 2Testing Compressed Air Lines for Microbiological Contamination 3Testing Compressed Air Lines for Microbiological Contamination 4Testing Compressed Air Lines for Microbiological Contamination 5Testing Compressed Air Lines for Microbiological Contamination 6Testing Compressed Air Lines for Microbiological Contamination 7Glossary for The BioPharm Guide to Fermentation and Cell Culture 2Glossary for The BioPharm Guide to Fermentation and Cell Culture 3Glossary for The BioPharm Guide to Fermentation and Cell Culture 4Glossary for The BioPharm Guide to Fermentation and Cell Culture 5Glossary for The BioPharm Guide to Fermentation and Cell Culture 6Glossary for The BioPharm Guide to Fermentation and Cell Culture 7Glossary for The BioPharm Guide to Fermentation and Cell Culture 8Glossary for The BioPharm Guide to Fermentation and Cell Culture 9Glossary for The BioPharm Guide to Fermentation and Cell Culture 10Glossary for The BioPharm Guide to Fermentation and Cell Culture 11Glossary for The BioPharm Guide to Fermentation and Cell Culture 12Glossary for The BioPharm Guide to Fermentation and Cell Culture 13Glossary for The BioPharm Guide to Fermentation and Cell Culture 14Glossary for The BioPharm Guide to Fermentation and Cell Culture 15Glossary for The BioPharm Guide to Fermentation and Cell Culture 16Gram Quantities of MAb Produced with Simple Bioreactor in Serum-Free Perfusion Culture Replacing Ascitic Fluid Production 2Hybridoma Cell Culture Application Using a BioFlo 110 Benchtop Bioreactor 2Hybridoma Cell Culture Application Using a BioFlo 110 Benchtop Bioreactor 3Hybridoma Cell Culture Application Using a BioFlo 110 Benchtop Bioreactor 4Hybridoma Cell Culture Application Using a BioFlo 110 Benchtop Bioreactor 5Hybridoma Cell Culture Application Using a BioFlo 110 Benchtop Bioreactor 6
... creates isogenic cell lines all transfected clone...rest. This homogeneous expression is demonstrated ... the coding sequence for chloramphenicol-acetyl tr...transfected into Flp-In-293 cells. Western blot an...
Growth Medium / Media
csiRNA By Request,1500 RNAi Reactions from Panomics
Recombinant Rat Leptin, CF
Biology Products: